|

Direct Oral Anticoagulants Clinical Trials

2 actively recruiting trials

Also known as: apixaban, dabigatran, edoxaban or rivaroxaban

Pipeline

Phase 3: 1Phase 4: 1

Top Sponsors

  • University of Birmingham1
  • University Hospital, Brest1

Indications

  • High-risk Patients1
  • JAK2 V617F1
  • Prefibrotic/Early Primary Myelofibrosis1
  • Heart Disease1
  • Atrial Fibrillation1

Other2 trials

AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms
Phase 3
Preventing Stroke, Premature Death and Cognitive Decline in a Broader Community of Patients With Atrial Fibrillation
Phase 4

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.